PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor t...

Full description

Bibliographic Details
Main Authors: Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Format: Article
Language:English
Published: Nature Publishing Group 2020-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-19810-w

Internet

https://doi.org/10.1038/s41467-020-19810-w

Similar Items